进入秋季，过敏高发，很多人会出现皮肤瘙痒、红疹，鼻子发痒、老打喷嚏，甚至喘息、胸闷，夜间或者晨起咳嗽加重等症状。医生提醒，换季 要做好过敏预防和调理，如果症状持续不缓解或加重，需及时就医。 易过敏人群还应日常做好个人防护和生活调理。医生建议，关注当地的花粉指数，避免在花粉浓度高峰期（如清晨）进行户外活动；外出时佩戴 口罩，回家后及时清洗鼻腔和面部，减少与过敏原的接触；定期清洗空调滤网和床单被套，保持室内通风；尽量穿宽松、透气的衣物，避免毛织 品对皮肤产生刺激；保持清淡饮食，尽量避免食用海鲜、花生等易致敏的食物。（记者邹欣媛） 宁夏医科大学总医院副院长、呼吸与危重症医学科主任医师陈娟说，秋季空气中的花粉、蒿草和霉菌孢子等过敏原增多，同时昼夜温差变大，冷 空气刺激鼻黏膜导致血管收缩，天气干燥引起皮肤屏障功能下降，很容易诱发过敏性鼻炎、哮喘或皮肤过敏。病情一发作直接影响睡眠质量、工 作效率。 "一些患者觉得过敏症状反反复复，索性不去理会，殊不知个别部位过敏如不及时治疗，可能会出现更为严重的过敏性疾病症状，比如过敏性鼻炎 加重后，会出现过敏性结膜炎，还会蔓延到支气管，伴随着哮喘的出现。"陈娟说。 医生提醒，如果已经出 ...

Financial Data and Key Metrics Changes - For Q1 2025, the company recorded total revenue of $8 million, with $7.8 million coming from U.S. net product revenue for Nefi, indicating a strong start to the year [20][24] - The company reported a net loss of $33.9 million or $0.35 per share for the first quarter [24] - Cash, cash equivalents, and short-term investments stood at $275.7 million as of March 31, 2025, providing an operating runway of at least three years [25] Business Line Data and Key Metrics Changes - Nefi generated $7.8 million in U.S. net product revenue in Q1 2025, reflecting growing demand among healthcare providers and patients [6][20] - The company has expanded commercial insurance coverage from 27% to 57% during the quarter, with ongoing discussions for further coverage [7][15] Market Data and Key Metrics Changes - The U.S. market potential for Nefi is estimated at $3 billion, with 6.5 million patients prescribed epinephrine in the past three years and an additional 13.5 million diagnosed patients without prescriptions [6] - The company aims to achieve 80% commercial lives coverage by Q3 2025, with current coverage at 57% without prior authorization [48] Company Strategy and Development Direction - The company is focused on deepening physician engagement, expanding access, and establishing a global commercial footprint for Nefi [12] - A comprehensive direct-to-consumer campaign titled "Hello Nefi, Goodbye Needles" is set to launch, aimed at raising awareness and driving prescription growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum from early revenue and physician testimonials, reinforcing the belief that Nefi is a transformative product [26] - The company anticipates an inflection point in sales during Q3 2025, particularly with the launch of the one-milligram dose and the DTC campaign [65] Other Important Information - The company plans to invest $40 million to $50 million in the DTC campaign for the remainder of 2025, with expectations of seeing benefits starting in Q3 [22][23] - The co-promotion agreement with ALK will allow the company to retain full control over U.S. commercialization while expanding its promotional network [21][75] Q&A Session Summary Question: How much of the Q1 sales figure is attributed to inventory? - Management indicated that Q1 numbers were minimally influenced by inventory, with steady inventories observed [30] Question: What would the gross to net discount look like in Q1? - The gross to net discount was around 60% for Q1, expected to decrease to closer to 50% as payer coverage improves [33] Question: Can you confirm that there are no prior auth requirements for access to Nefi for 57% of commercial lives? - Management confirmed that 57% have coverage without prior authorization, while about 90% have coverage when including those requiring prior authorization [38] Question: What is the expected cost of goods sold (COGS) as inventory is worked through? - COGS is expected to increase slightly as no-cost inventory is utilized over the next 18 months [40] Question: How is the Nefi Experience Program helping convert physicians into prescribers? - The program has enrolled over 2,500 physicians, with positive feedback and high prescription rates among participants [44] Question: How are payer negotiations tracking against the goal of 80% commercial lives by Q3? - Management is still negotiating with several payers, including Caremark and Aetna, to achieve the target [47] Question: What is the current market share and where do you hope to be by the end of the year? - The company currently holds about 1.3% market share overall, with higher shares among targeted physicians [73]

又到了 "花粉刺客" 的活跃季，也是各种过敏性疾病的高发期。很多人可能觉得打喷嚏、流鼻涕、 眼睛痒痒都不过是小事情，但若不及时治疗，"小毛病"也可能引发大问题。 今天，麻醉科医生就来介绍两种新型的过敏治疗方法，帮助大家摆脱过敏困扰，大胆走出家门享受 春天。 四大症状拉响鼻炎警报 鼻痒难耐 常伴眼睛痒、流泪，严重时眼皮肿成"悲伤蛙"。 鼻涕开启水龙头模式 清涕如泉涌，日均用纸量激增300%。 鼻塞严重 单/双侧鼻孔堵塞，部分患者可能出现嗅觉减退。 过敏难受还能求助麻醉科？ 很多过敏患者做了各种尝试，如联合使用抗过敏药、鼻喷药、眼药水等药物进行对症治疗。但症状 仍反复出现，甚至可能随着时间症状会进一步加重。在这种情况下，患者可以尝试其他的治疗方法，比 如星状神经节与蝶腭神经节疗法。 遭遇过敏原突袭时，过敏人群的身体会拉响"四级警报"。 连环喷嚏停不下来 突发性连打5-20个喷嚏，晨起尤为明显。 不适合人群：有鼻部手术史、鼻腔畸形及晕针恐惧症的患者。 文/高颖（北京友谊医院） 这两种疗法是麻醉治疗门诊常用的治疗疼痛的技术，对于治疗过敏有很好的效果，一针见效，关闭 患者的"过敏模式"。 过敏的本质是免疫系统错误地把花 ...